REGULATORY PERSPECTIVE AND CHALLENGES OF ADVANCED NOSE – TO- BRAIN DRUG DELIVERY SYSTEMS IN CNS THERAPEUTICS
International Journal of Biological and Pharmaceutical Sciences Archive · 01.11.2026 · 12 (2) · 104
DOI: 10.53771/ijbpsa.2026.12.2.0105 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Biological and Pharmaceutical Sciences Archive, online erschienen am 01.11.2026. Verfasst von Jadhav Pratiksha Sanjay und 5 weiteren Autor:innen. Die Arbeit nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).
Abstract (Originalsprache)
The central nervous system (CNS) which includes the brain and spinal cord controls vital functions of the human body. Treating CNS disorders is still hard because the blood–brain barrier (BBB) blocks medicines from reaching the brain. Conventional ways to give medicine, such as pills or injections often fail to deliver drug to the right spot. That is why nose to brain drug delivery has become a non invasive way to bring medicines straight to the CNS. The close anatomical and physiological connections between the nose and the brain through the olfactory and trigeminal nerves allow the drug to reach the CNS directly and reduce dependence on the bloodstream. This approach can also avoid first pass liver metabolism. May make treatment easier for patients. New formulations like nanoparticles, liposomes, solid lipid nanoparticles, nanostructured lipid carriers and nano emulsions are being studied to improve drug stability, nasal absorption and CNS targeting. These advances face many obstacles: the nose’s mucociliary clearance, limited drug spread difficulty proving direct nose to brain movement, identifying nanocarrier properties, standardizing formulations, batch variation and checking long term safety. From a point of view a detailed evaluation of quality, safety and effectiveness is essential. Key elements such as quality features, analytical tests, stability studies, manufacturing control, validated preclinical models, pharmacokinetic and pharmacodynamic data and appropriate clinical trials are needed for product development. Harmonized regulations and consistent testing methods are also critical to bring these formulations into clinical use
Zitieren
APA
Sanjay, J. P., Shrikrishna, K. S., Naushad, K. M., Jaywant, J. S., Shantaram, S. P., & Ramdas, K. R. (2026). REGULATORY PERSPECTIVE AND CHALLENGES OF ADVANCED NOSE – TO- BRAIN DRUG DELIVERY SYSTEMS IN CNS THERAPEUTICS. International Journal of Biological and Pharmaceutical Sciences Archive, 12(2), 104. https://doi.org/10.53771/ijbpsa.2026.12.2.0105
Vancouver
Sanjay JP, Shrikrishna KS, Naushad KM, Jaywant JS, Shantaram SP, Ramdas KR. REGULATORY PERSPECTIVE AND CHALLENGES OF ADVANCED NOSE – TO- BRAIN DRUG DELIVERY SYSTEMS IN CNS THERAPEUTICS. International Journal of Biological and Pharmaceutical Sciences Archive. 2026;12(2):104. doi:10.53771/ijbpsa.2026.12.2.0105
BibTeX
@article{Sanjay2026,
author = {Sanjay, Jadhav Pratiksha and Shrikrishna, Khope Sanjana and Naushad, Khan Mntasha and Jaywant, Jadhav Sanjana and Shantaram, Shelake Poonam and Ramdas, Khairnar Rohit},
title = {REGULATORY PERSPECTIVE AND CHALLENGES OF ADVANCED NOSE – TO- BRAIN DRUG DELIVERY SYSTEMS IN CNS THERAPEUTICS},
journal = {International Journal of Biological and Pharmaceutical Sciences Archive},
year = {2026},
volume = {12},
number = {2},
pages = {104},
doi = {10.53771/ijbpsa.2026.12.2.0105}
}
EUVIMED